An investigation for investors in Kite Pharma Inc (NASDAQ:KITE) shares over potential securities laws violations by Kite Pharma Inc was announced and NASDAQ:KITE stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/24/2017 -- Kite Pharma Inc is under investigation over possible securities laws violations. The investigation was announced for investors in NASDAQ:KITE shares ov in connection with certain financial statements made by Kite Pharma Inc.
Investors who purchased shares of Kite Pharma Inc (NASDAQ:KITE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kite Pharma Inc (NASDAQ:KITE) concerning whether certain statements by Kite Pharma Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 8, 2017, Kite Pharma Inc disclosed that a cancer patient had died in April 2017 from brain swelling following treatment with the Company's CAR-T therapy KTE-C19. Shares of Kite Pharma Inc (NASDAQ:KITE) declined on May 9, 2017 to $66.75 per share.
Those who purchased shares of Kite Pharma Inc (NASDAQ:KITE) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com